Portal de Periódicos da CAPES

Mutation in human CLPX elevates levels of δ- aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria

2017; National Academy of Sciences; Volume: 114; Issue: 38 Linguagem: Inglês

10.1073/pnas.1700632114

1091-6490

Yvette Y. Yien, Sarah Ducamp, Lisa N. van der Vorm, Julia R. Kardon, Hana Manceau, Caroline Kannengiesser, Hector A. Bergonia, Martin D. Kafina, Zoubida Karim, Laurent Gouya, Tania A. Baker, Hervé Puy, John D. Phillips, Gaël Nicolas, Barry H. Paw,

Neonatal Health and Biochemistry

Significance Although heme synthesis is ubiquitous, specific regulatory mechanisms couple heme production to cellular demand and environmental conditions. The importance of these regulatory mechanisms is highlighted by clinical variability in porphyrias caused by loss-of-function mutations in heme synthesis enzymes. Heme synthesis is also controlled by the mitochondrial AAA+ unfoldase ClpX, which participates in both heme-dependent degradation of δ-aminolevulinate synthase (ALAS) and ALAS activation. This study reports a human familial mutation in CLPX that contributes to erythropoietic protoporphyria (EPP) by partially inactivating CLPX. Reduced CLPX activity increases ALAS post-translational stability, causing pathological accumulation of protoporphyrin IX (PPIX) in human patients. Our results thus identify an additional gene that promotes PPIX overproduction and EPP and highlight the complex gene network contributing to disorders of heme metabolism.